

Chapter 176

Superficial Cutaneous Infections and Pyodermas

Noah Craft

REFERENCES

1. Foster TJ: Immune evasion by staphylococci. *Nat Rev Microbiol* **3**(12):948-958, 2005
2. Yang ES et al: Body site colonization in patients with community-associated methicillin-resistant *Staphylococcus aureus* and other types of *S. aureus* skin infections. *Clin Microbiol Infect* **16**(5):425-431, 2009
3. Kluytmans JA et al: Nasal carriage of *Staphylococcus aureus* as a major risk factor for wound infections after cardiac surgery. *J Infect Dis* **171**(1):216-219, 1995
4. Pujol M et al: Nosocomial *Staphylococcus aureus* bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. *Am J Med* **100**(5):509-516, 1996
5. Bradley SF: *Staphylococcus aureus* infections and antibiotic resistance in older adults. *Clin Infect Dis* **34**(2):211-216, 2002
6. Manders SM: Toxin-mediated streptococcal and staphylococcal disease. *J Am Acad Dermatol* **39**(3):383-398; quiz 399-400, 1998
7. McCormick JK, Yarwood JM, Schlievert PM: Toxic shock syndrome and bacterial superantigens: An update. *Annu Rev Microbiol* **55**:77-104, 2001
8. Leung DY et al: The role of superantigens in human diseases: Therapeutic implications for the treatment of skin diseases. *Br J Dermatol* **139**(Suppl. 53):17-29, 1998
9. Deleo FR et al: Community-associated methicillin-resistant *Staphylococcus aureus*. *Lancet* **375**(9725):1557-1568, 2010
10. Kauffman CA et al: Attempts to eradicate methicillin-resistant *Staphylococcus aureus* from a long-term-care facility with the use of mupirocin ointment. *Am J Med* **94**(4):371-378, 1993
11. DeLeo FR, Diep BA, Otto M: Host defense and pathogenesis in *Staphylococcus aureus* infections. *Infect Dis Clin North Am* **23**(1):17-34, 2009
12. Amagai M et al: Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. *Nat Med* **6**(11):1275-1277, 2000
13. Gisby J, Bryant J: Efficacy of a new cream formulation of mupirocin: Comparison with oral and topical agents in experimental skin infections. *Antimicrob Agents Chemother* **44**(2):255-260, 2000
14. Yang LP, Keam SJ: Spotlight on retapamulin in impetigo and other uncomplicated superficial skin infections. *Am J Clin Dermatol* **9**(6):411-413, 2008
15. Schofer H, Simonsen L: Fusidic acid in dermatology: An updated review. *Eur J Dermatol* **20**(1):6-15, 2010
16. Koning S et al: Interventions for impetigo. *Cochrane Database Syst Rev* (2):CD003261, 2004
17. Cunningham MW: Pathogenesis of group A streptococcal infections. *Clin Microbiol Rev* **13**(3):470-511, 2000
18. McFadden JP et al: Psoriasis and streptococci: The natural selection of psoriasis revisited. *Br J Dermatol* **160**(5):929-937, 2009
19. Berkower C et al: Expression of different group A streptococcal M proteins in an isogenic background demonstrates diversity in adherence to and invasion of eukaryotic cells. *Mol Microbiol* **31**(5):1463-1475, 1999
20. Currie BJ: Group A streptococcal infections of the skin: Molecular advances but limited therapeutic progress. *Curr Opin Infect Dis* **19**(2):132-138, 2006
21. Kaplan EL, Johnson DR, Cleary PP: Group A streptococcal serotypes isolated from patients and sibling contacts during the resurgence of rheumatic fever in the United States in the mid-1980s. *J Infect Dis* **159**(1):101-103, 1989
22. Dillon HC Jr: Impetigo contagiosa: Suppurative and non-suppurative complications. I. Clinical, bacteriologic, and epidemiologic characteristics of impetigo. *Am J Dis Child* **115**(5):530-541, 1968
23. Wannamaker LW: Differences between streptococcal infections of the throat and of the skin (second of two parts). *N Engl J Med* **282**(2):78-85, 1970

24. Bessen D, Fischetti VA: A human IgG receptor of group A streptococci is associated with tissue site of infection and streptococcal class. *J Infect Dis* **161**(4):747-754, 1990
25. Schlievert PM: Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. *J Allergy Clin Immunol* **108**(4 Suppl.):S107-S110, 2001
26. Ferrieri P et al: Natural history of impetigo. I. Site sequence of acquisition and familial patterns of spread of cutaneous streptococci. *J Clin Invest* **51**(11):2851-2862, 1972
27. Britton JW, Fajardo JE, Krafte-Jacobs B: Comparison of mupirocin and erythromycin in the treatment of impetigo. *J Pediatr* **117**(5):827-829, 1990
28. Seppala H et al: The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. *N Engl J Med* **337**(7):441-446, 1997
29. Rehder PA, Eliezer ET, Lane AT: Perianal cellulitis. Cutaneous group A streptococcal disease. *Arch Dermatol* **124**(5):702-704, 1988
30. Honig PJ: Guttate psoriasis associated with perianal streptococcal disease. *J Pediatr* **113**(6):1037-1039, 1988
31. Woroszylski A et al: Staphylococcal blistering dactylitis: Report of two patients. *Pediatr Dermatol* **13**(4):292-293, 1996
32. Takama H et al: Pitted keratolysis: Clinical manifestations in 53 cases. *Br J Dermatol* **137**(2):282-285, 1997
33. Blaise G et al: Corynebacterium-associated skin infections. *Int J Dermatol* **47**(9):884-890, 2008
34. Wharton JR, Wilson PL, Kincannon JM: Erythrasma treated with single-dose clarithromycin. *Arch Dermatol* **134**(6):671-672, 1998